GC Green Cross Completes Additional Production of Corona 19 Blood Device
It announced on the 14th that it has completed production of the second batch.
[Introduction of the case / Reporter Park Yeon-pa] = GC Green Cross's novel coronavirus infectious disease-19 (Corona 19) blood system has completed additional production.
GC Green Cross (CEO Heo Eun-cheol) announced on the 14th that it has completed the production of the second batch of the COVID-19 blood system drug “GC5131A”.
The blood system drug is made by extracting antibodies with immunogenicity from the plasma of a cure for Corona 19, and the plasma used for this production amounts to 240 liters. This is about four times more than the first input.
The company said that unlike the first batch made for clinical trial purposes, this production is mainly for the use of'treatment' for corona19 patients in the medical field. He added that drugs in clinical trials can be used for patients who are in danger of life or who do not have alternative treatments under the approval of the Ministry of Food and Drug Safety.
Due to the nature of the drug formulation, it can be produced only as long as the plasma of a cure for COVID-19 is secured. In order to secure plasma, GC Green Cross has expanded its plasma blood collection facilities from four existing medical institutions to 46 “blood donation houses” in cooperation with health authorities and the Red Cross. In fact, whether or not production will continue in the future depends on the “power” of the cured person who overcomes Corona 19.
GC Green Cross Head of Medicine, Jin Kim, said, "The blood system is a therapeutic agent created by the power of our people. We ask for your active interest and participation so that therapies to be used in the medical field can be developed quickly."
Meanwhile, those who want to donate plasma can apply through the website and call center.
<저작권자 ⓒ 사건의내막 무단전재 및 재배포 금지>